Avoiding the Risks of Being Wrong in Drug Discovery

CHRISTINE DE VRIES - SCHEIDEGGER | May 5, 2017

article image
In a recent case study featuring a mid-market biopharma company, a pre-clinical research leader explains that in order to avoid the risks of being wrong when investigating potential new molecules and validating methods he needs reliable, up to date and comprehensive scientific information.

Spotlight

Christies Care Ltd

Consultus Care & Nursing is a nationwide specialist in the provision of Live-in Carers and Nurses. Established in 1962, we have decades of experience in providing quality live-in care for people who want a real alternative to care homes, inconsistent daily care and extended hospital stays. We offer our clients the choice to receive one-to-one care or nursing within the comfort and familiarity of their own home. Live-in Care For over 50 years we have been providing Live-in Carers to support people who wish to maintain an independent lifestyle in their own home. Our Live-in Carers offer individuals or couples a welcome and reassuring alternative to care homes. It’s a one-to-one service shaped by each individual's situation and needs, extending their independence and enabling daily freedom of choice. Many healthcare professionals agree their patients recover more quickly following illness or an operation when they’re in the comfort of their own homes. Our carers provide help with personal

OTHER ARTICLES

How Pharma Companies Can Scale Up Their Knowledge Discovery with Semantic Similarity Search

Article | March 6, 2020

Pharma has deep roots in human history with centuries of folk pharmaceutical knowledge offering a hit-and-miss range of natural remedies. But the industry as we know it today actually emerged in the second half of the 19th century when the world’s first factory for the sole production of medicines was found. By the late 19th and early 20th century, some chemical companies had already begun using research labs to explore the medical applications for their products. Fast forward to today and the pharmaceutical sector is a global trillion-dollar industry. However, to ensure the safety and efficacy of drugs, the process of drug discovery and development is under extensive scrutiny and control on both national and global levels.

Read More

Advance Your Pharma Supply Chain Planning during a Pandemic

Article | March 6, 2020

One predominant and common element within our pharmaceutical industry, is our devotions to patients. Within supply chain there is always a focus on ensuring the right product is delivered to the right place at the right time in order to ensure patient safety and the continuity of medicinal supplies. With the spread of COVID-19 across 117 countries and counting, every supply chain needs to evaluate their global footprint and develop contingency plans within their end to end operations.

Read More
VIEWS AND ANALYSIS

New Dimensions of Clinical Trial Optimization

Article | March 6, 2020

For much of the past three decades, even as methodologies for clinical trial design have advanced and refined, the idea of the optimized clinical trial has centered on optimal patient samples, target enrollment rates, and generally the most efficient uses of scarce resources in the form of patients. Yet anyone who has had to design and optimize a clinical trial, knows that trial optimization occurs within an ecosystem of choices; a series of choices that stretch from the time it takes to implement a clinical trial and submit clinical data for analysis, to general concerns about the cost and power of a clinical trial. A true clinical trial optimization process would try to unify a number of these choices into a single framework for trial optimization. The complexity of clinical trial optimization comes from the need to align priorities on the one hand, and to understand opportunities on the other. We know that at a very general level, clinical operations specialists benefit from simplicity in clinical trial design, and that commercial teams prefer shorter clinical trials to longer ones. We also know that the statistical design of a clinical trial can influence both simplicity and duration. Yet how many sponsors have their clinical operations and commercial teams, sit with their R&D teams to review various statistically nuanced design options? For many sponsors, the reason this process does not occur as often as it should, is because the nuanced statistical parameters of a clinical trial design are very difficult to communicate to non-statisticians. Yet a trial optimization tool like Solara, equipped with data visualizations and the ability to see tradeoffs intuitively, can overcome this challenge. The real challenge is often convincing the non-statistician that they have a stake in clinical trial design. Cytel recently had a client that thought it needed a sample size re-estimation design, because it had a very strict limit on the number of patients it could enroll. After a few hours of working with Solara, though, a statistician discovered that a much simpler Group Sequential Design would deliver comparable power using about the same number of patients. The gains from the more complex design were minimal from the optimization perspective, when understood as the eco-system of choices. Similarly, most commercial teams pressure their clinical trial designers to have the most accelerated clinical trial imaginable, but as we all know, the longer the clinical trial the more likely there will be a higher number of events that demonstrate the effectiveness of a new medicine. So commercialization teams have a stake in longer clinical trials, even when their rule of thumb is to shorten them. Therefore, it is absolutely essential to communicate the benefits of various statistical designs to multiple stakeholders in a way that makes tradeoffs clear. Aligning on priorities early during the clinical trial design process is essential to selecting the optimal clinical trial. Yet for this statisticians need to be equipped for both a strategic and communicative role in the R&D process.

Read More

Roche Prepares to Launch COVID-19 Antibody Test System

Article | March 6, 2020

Swiss pharma giant Roche is joining the race to develop a test for COVID-19 antibodies in people who have been exposed to the disease. This morning, Roche announced the development and upcoming launch of its Elecsys Anti-SARS-CoV-2 serology test to detect antibodies in people who have been exposed to the SARS-CoV-2, the virus that causes COVID-19. Roche is eying May for the launch of the test in Europe and is in talks with the U.S Food and Drug Administration for emergency approval of the system. Antibody testing is central to help identify people who have been infected by the virus, especially those who may have been infected but did not display symptoms, the company said. Roche noted that as more information becomes available about immunity levels to COVID-19, society can return to a sense of normal much more quickly. Roche’s test will join a number of other antibody tests that have recently come on the market. Earlier this month the U.S. Food and Drug Administration approved the first blood test for COVID-19 antibodies.

Read More

Spotlight

Christies Care Ltd

Consultus Care & Nursing is a nationwide specialist in the provision of Live-in Carers and Nurses. Established in 1962, we have decades of experience in providing quality live-in care for people who want a real alternative to care homes, inconsistent daily care and extended hospital stays. We offer our clients the choice to receive one-to-one care or nursing within the comfort and familiarity of their own home. Live-in Care For over 50 years we have been providing Live-in Carers to support people who wish to maintain an independent lifestyle in their own home. Our Live-in Carers offer individuals or couples a welcome and reassuring alternative to care homes. It’s a one-to-one service shaped by each individual's situation and needs, extending their independence and enabling daily freedom of choice. Many healthcare professionals agree their patients recover more quickly following illness or an operation when they’re in the comfort of their own homes. Our carers provide help with personal

Events